Baird analyst Evan Stover raised the firm’s price target on Catalent (CTLT) to $82 from $75 and keeps an Outperform rating on the shares. The analyst said they provided a mixed bag update, though good vibes win out largely due to the Moderna (MRNA) extension and expansion beyond COVID.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTLT: